Non-hematological Adverse Events of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Mehrdad Payandeh, Edris Sadeghi, Masoud Sadeghi
2015 Journal of Applied Pharmaceutical Science  
The aim of this study is survey of effects of Imatinib with dose 400 mg per day after 6 months in the patients with CML chronic phase. Between of 2010 -2014, fifty four patients with high risk CML referred to Taleghani hospital in Kermanshah, Iran. We used the questionnaire about adverse events (AEs) of Imatinib capsule (Cipla manufacture, India) in these patients. For grading AEs, We used Common Terminology Criteria for AEs (CTCAE) manuscript (low AE equals grade 1, 2: high AE equals 3, 4 and
more » ... rade 5 is optional) that diagram related to them was plotted with Excel 2007 software. 54 patients that referred to hospital, 27 patients were female and 27 patients were male. Mean of age for the patients was 45.7 ± 13.8 years (range, 23 to 78 years). Fatigue, (66.7%), myalgia (61.6%), joint pain (61.6%) and cramp (57.4%) are the most AEs in the patients after treatment of Imatinib. In the future studies we should evaluate non-hematological AEs for Imatinib in a lot of CML patients and apply to CTCAE manuscript exactly.
doi:10.7324/japs.2015.50213 fatcat:2qdks23j6vcfjmkfaehpqw3iwu